PD-1

[Cancer Cell] Researchers proposed that lactic acid in the highly glycolytic tumor microenvironment (TME) was an active checkpoint for the function of regulatory T cells in the TME via upregulation of PD-1 expression.

[Akeso, Inc. (PR Newswire, Inc.)] Akeso, Inc. announced that Ligufalimab and Ivonescimab have obtained approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China to initiate a Phase II clinical trial with chemotherapy as first-line therapy for unresectable locally advanced or metastatic triple negative breast cancer.

[Developmental Cell] Scientists reported that the adhesion molecule intercellular adhesion molecule 1 (ICAM-1) co-localized with programmed death ligand 1 (PD-L1) on the exosomes; both ICAM-1 and PD-L1 were upregulated by interferon-γ.

[Evaxion Biotech, Inc.] Evaxion Biotech, Inc.announced it has received clearance from the Australia Therapeutic Goods Administration to initiate a Phase IIb trial of its patient specific cancer immunotherapy EVX-01 in combination with Merck & Co., Inc.’s anti-PD-1 therapy KEYTRUDA®

[Current Opinion in Oncology] Scientists focus on new immunotherapeutic approaches studied in advanced melanoma previously treated by anti-programmed cell death 1 (PD-1) receptor or anti-cytolytic T-lymphocyte-associated protein 4 (CTLA-4) antibodies.

[Reproductive Sciences] Researchers assessed the correlation between immune infiltration status, chemotherapeutics sensitivity, immune checkpoint proteins, and the signature.